Staphylococcus aureus is a prevalent cause of bacterial infections associated with indwelling medical devices. RNA III inhibiting peptide (RIP) is known to inhibit S. aureus pathogenesis by disrupting quorum-sensing mechanisms. RIP was tested in the present study for its ability to inhibit S. aureus biofilm formation in a rat Dacron graft model. The activity of RIP was synergistic with those of antibiotics for the complete prevention of drug-resistant S. aureus infections.
RNA III inhibiting peptide inhibits in vivo biofilm formation by drug-resistant Staphylococcus aureus / Giacometti, Andrea; Cirioni, Oscar; Gov, Y; Ghiselli, Roberto; Del Prete, Ms; Mocchegiani, Federico; Saba, Vittorio; Orlandoni, Francesco; Scalise, Giorgio; Balaban, N; Dell'Acqua, G.. - In: ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. - ISSN 0066-4804. - STAMPA. - 47:6(2003), pp. 1979-1983.
RNA III inhibiting peptide inhibits in vivo biofilm formation by drug-resistant Staphylococcus aureus.
GIACOMETTI, Andrea;CIRIONI, OSCAR;GHISELLI, ROBERTO;MOCCHEGIANI, FEDERICO;SABA, Vittorio;ORLANDONI, FRANCESCO;SCALISE, Giorgio;
2003-01-01
Abstract
Staphylococcus aureus is a prevalent cause of bacterial infections associated with indwelling medical devices. RNA III inhibiting peptide (RIP) is known to inhibit S. aureus pathogenesis by disrupting quorum-sensing mechanisms. RIP was tested in the present study for its ability to inhibit S. aureus biofilm formation in a rat Dacron graft model. The activity of RIP was synergistic with those of antibiotics for the complete prevention of drug-resistant S. aureus infections.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
